Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Knight, J. S.
  • Zhao, W. P.
  • Luo, W.
  • Subramanian, V.
  • O'Dell, A. A.
  • Yalavarthi, S.
  • Hodgin, J. B.
  • Eitzman, D. T.
  • Thompson, Paul
  • Kaplan, M. J.

publication date

  • July 2013

journal

  • Journal of Clinical Investigation  Journal

abstract

  • Recent evidence suggests that enhanced neutrophil extracellular trap (NET) formation activates plasmacytoid dendritic cells and serves as a source of autoantigens in SLE. We propose that aberrant NET formation is also linked to organ damage and to the premature vascular disease characteristic of human SLE. Here, we demonstrate enhanced NET formation in the New Zealand mixed 2328 (NZM) model of murine lupus. NZM mice also developed autoantibodies to NETs as well as the ortholog of human cathelicidin/LL37 (CRAMP), a molecule externalized in the NETs. NZM mice were treated with Cl-amidine, an inhibitor of peptidylarginine deiminases (PAD), to block NET formation and were evaluated for lupus-like disease activity, endothelial function, and prothrombotic phenotype. Cl-amidine treatment inhibited NZM NET formation in vivo and significantly altered circulating autoantibody profiles and complement levels while reducing glomerular IgG deposition. Further, Cl-amidine increased the differentiation capacity of bone marrow endothelial progenitor cells, improved endothelium-dependent vasorelaxation, and markedly delayed time to arterial thrombosis induced by photochemical injury. Overall, these findings suggest that PAD inhibition can modulate phenotypes crucial for lupus pathogenesis and disease activity and may represent an important strategy for mitigating cardiovascular risk in lupus patients.

subject areas

  • Animals
  • Autoantibodies
  • Bone Marrow Cells
  • Cardiovascular Diseases
  • Carotid Artery Thrombosis
  • Cell Differentiation
  • Cells, Cultured
  • Disease Models, Animal
  • Endothelium
  • Female
  • Humans
  • Hydrolases
  • Injections, Subcutaneous
  • Lupus Erythematosus, Systemic
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Neutrophils
  • Ornithine
  • Phenotype
  • Stem Cells
  • Vasodilation
scroll to property group menus

Identity

PubMed Central ID

  • PMC3696545

International Standard Serial Number (ISSN)

  • 0021-9738

Digital Object Identifier (DOI)

  • 10.1172/jci67390

PubMed ID

  • 23722903
scroll to property group menus

Additional Document Info

start page

  • 2981

end page

  • 2993

volume

  • 123

issue

  • 7

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support